Chemometec Q4: Ledelsen venter +18% vækst i EBITDA-driftsoverskud i det nye regnskabsår
Accordingly, our business will become more diversified, providing a stronger basis for future growth – both in our existing and in new market segments,” says Martin Helbo Behrens, CEO.